Skip to main content

Advertisement

SpringerLink
Log in

Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia

  • Original Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Alemtuzumab (Campath-1H) is a monoclonal antibody (MAb) that shows its most powerful effects in clearing malignant CD52-bearing cells from the blood and bone marrow. Attention had therefore focused on the use of alemtuzumab in the treatment of B-cell chronic lymphocytic leukemia (B-CLL), in which symptoms are the result of an expansion of a CD1a+/CD5+/CD23+/CD52+ malignant clone, causing lymphocytosis in the circulation and pervasive infiltration of the bone marrow. In clinical trials, in heavily pretreated patients, alemtuzumab was effective, producing responses in about one-third of patients who had failed to respond previously to chemotherapy, including fludarabine. In addition, there was an even higher clinical effect in the bone marrow. Alemtuzumab treatment has also allowed patients with advanced disease to proceed to stem cell transplantation, and preliminary data indicate that alemtuzumab is highly effective in previously untreated patients with B-CLL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Montserrat, E. (2001). Developing risk-adapted strategies for chronic lymphocytic leukemia. In: Chronic Lymphoid Leukemias (B.D. Cheson, ed.), Vol. 1, pp. 377–391, Marcel Dekker, New York.

    Google Scholar 

  2. Johnson, S., et al. (1996). Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL [see comments]. Lancet 347(9013):1432–1438.

    PubMed  CAS  Google Scholar 

  3. Rai, K.R., et al. (2000). Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 343(24):1750–1757.

    Article  PubMed  CAS  Google Scholar 

  4. Riechmann, L., Clark, M., Waldmann, H. and Winter, G. (1988). Reshaping human antibodies for therapy. Nature 332(6162):323–327.

    Article  PubMed  CAS  Google Scholar 

  5. Rossmann, E.D., et al. (2001). Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol. J. 2:300–306.

    Article  PubMed  CAS  Google Scholar 

  6. Ginaldi, L., et al. (1998). Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk. Res. 22(2):185–191.

    Article  PubMed  CAS  Google Scholar 

  7. Hale, G. (2001). The CD52 antigen and development of the Campath antibodies. Cytotherapy 3(3):137–143.

    Article  PubMed  CAS  Google Scholar 

  8. Rowan, W., Tite, J., Topley, P. and Brett, S.J. (1998). Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 95(3):427–436.

    Article  PubMed  CAS  Google Scholar 

  9. Rai, K.R. and Stephenson, J. (2001). Monoclonal antibodies in cancer: the development of Campath-1H. In: Campath-1H: Emerging Frontline Therapy in Chronic Lymphocytic Leukemia. Parthenon Publishing Group, Lancaster, UK.

    Google Scholar 

  10. Dyer, M.S.J., Hale, G., Marcus, R. and Waldmann, H. (1990). Remission induction in patients with lymphoid malignancies using unconjugated Campath-1H monoclonal antibodies. Leuk. Lymphoma 2:179–193.

    Google Scholar 

  11. Dyer, M.J., Hale, G., Hayhoe, F.G. and Waldmann, H. (1989). Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 73(6):1431–1439.

    PubMed  CAS  Google Scholar 

  12. Rawstron, A.C., et al. (1997). Campath-1H therapy for patients with refractory chronic lymphocytic leukemia (CLL). Blood 90(Suppl. 1):529a.

    Google Scholar 

  13. Osterborg, A., et al. (1997). Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J. Clin. Oncol. 15(4):1567–1574.

    PubMed  CAS  Google Scholar 

  14. Bowen, A.L., et al. (1997). Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br. J. Haematol. 96(3):617–619.

    Article  PubMed  CAS  Google Scholar 

  15. Ferrajoli, A., et al. (2000). Phase II clinical trial of Campath-1H in refractory hematological malignancies expressing the surface antigen CD52. Proc. Am. Soc. Clin. Oncol. 19:8a.

    Google Scholar 

  16. Hoffman, M., Jansen, D. and Rai, K. (1999). Analysis of response to Campath-1H in patients with B-CLL progressing after fludarabine therapy. Hematol. Cell Ther. IWCLL 67, abstract P129.

  17. Rai, K. (2000). Campath-1H is an effective salvage therapy for fludarabine-failing B-CLL patients. Blood 96:abstract 703.

    Google Scholar 

  18. Pangalis, G.A., Dimopoulou, M.N., Angelopoulou, M.K. and Siakantaris, M.P. (2000). Campath-1H in B-chronic lymphocytic leukemia: report on a patient treated thrice in a 3 year period. Med. Oncol. 17:70–73.

    PubMed  CAS  Google Scholar 

  19. Keating, M.J., et al. (2002). Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood, in press.

  20. Cheson, B.D., et al. (1996). National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87(12):4990–4997.

    PubMed  CAS  Google Scholar 

  21. Keating, M., et al. (2002). Results of first salvage therapy for patients refractory to a Fludara regimen in chronic lymphocytic leukemia. Leuk. Lymphoma, in press.

  22. Flynn, J.M. and Byrd, J.C. (2001). Campath-1H monoclonal antibody therapy. Curr. Opin. Oncol. 12(6):574–581.

    Article  Google Scholar 

  23. Keating, M.J., et al. (1999). Multicenter study of Campath-1H in patients with chronic lymphocytic leukemia (B-CLL) refractory to fludarabine. Blood 94:abstract 3118.

    Google Scholar 

  24. Osterborg, A., et al. (1996). Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br. J. Haematol. 93(1):151–153.

    Article  PubMed  CAS  Google Scholar 

  25. Lundin, J., et al. (2000). CAMPATH-1H therapy of patients with previously untreated chronic lymphocytic leukemia (CLL). Ann. Oncol. 11(Suppl. 4):96.

    Google Scholar 

  26. Schey, S.A., Ahsan G., and Jones, R. (1999). Dose intensification and molecular responses in patients with chronic lymphocytic leukemia: a phase ll single center study. Bone Marrow Transplant. 24:989–993.

    Article  PubMed  CAS  Google Scholar 

  27. Visani, G., et al. (1999). Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. Br. J. Haematol. 105(3):775–779.

    Article  PubMed  CAS  Google Scholar 

  28. Dyer, M.J., et al. (1997). In vivo “purging” of residual disease in CLL with Campath-1H. Br. J. Haematol. 97(3):669–672.

    Article  PubMed  CAS  Google Scholar 

  29. Kennedy, S., et al. (1999). Campath-1H therapy in 29 patients with refractory CLL: “true” complete remission is an attainable goal. Blood 94(10, Suppl. 1):603a.

    Google Scholar 

  30. Kennedy, B., et al. (2000). Campath-1H with fludarabine: a novel, highly active combination in refractory CLL. Blood 96:abstract 4991.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Texas M. D. Anderson Cancer Center, Houston, TX

    Michael Keating

  2. Department of Oncology, Karolinska Hospital, SE-171 76, Stockholm, Sweden

    Anders Osterborg & Hakan Mellstedt

Authors
  1. Anders Osterborg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hakan Mellstedt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anders Osterborg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Osterborg, A., Mellstedt, H. & Keating, M. Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia. Med Oncol 19 (Suppl 2), S21–S26 (2002). https://doi.org/10.1385/MO:19:2S:S21

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1385/MO:19:2S:S21

Key Words

Search

Navigation